NeoSpect

RSS

depreotide

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for NeoSpect has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 18/11/2010

Authorisation details

Product details
Name
NeoSpect
Agency product number
EMEA/H/C/000263
Active substance
depreotide trifluoroacetate
International non-proprietary name (INN) or common name
depreotide
Therapeutic area (MeSH)
Radionuclide Imaging
Anatomical therapeutic chemical (ATC) code
V09IA05
Publication details
Marketing-authorisation holder
CIS bio international
Revision
10
Date of issue of marketing authorisation valid throughout the European Union
29/11/2000
Contact address

Route Nationale 306, Saclay
B.P. 32
F-91192 Gif sur Yvette Cedex
France

Product information

28/10/2010 NeoSpect - EMEA/H/C/000263 - N/0015

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Diagnostic radiopharmaceuticals

Therapeutic indication

This medicinal product is for diagnostic use only.
For scintigraphic imaging of suspected malignant tumours in the lung after initial detection, in
combination with CT scan or chest X-ray, in patients with solitary pulmonary nodules.

Assessment history

How useful was this page?

Add your rating